Virios Therapeutics inc   (VIRI)
Other Ticker:  
Price: $0.3417 $-0.03 -7.898%
Day's High: $0.384 Week Perf: -4.29 %
Day's Low: $ 0.33 30 Day Perf: -16.66 %
Volume (M): 279 52 Wk High: $ 2.42
Volume (M$): $ 95 52 Wk Avg: $0.91
Open: $0.38 52 Wk Low: $0.28

 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 19
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Virios Therapeutics Inc
Virios Therapeutics, Inc. is a biotechnology company that specializes in the development of innovative therapies for autoimmune diseases and chronic viral infections. The company focuses on creating targeted protein therapeutics designed to modulate and regulate the immune system's response. These therapies aim to provide an effective and safe treatment option for patients suffering from conditions such as rheumatoid arthritis, lupus, and other autoimmune disorders. Virios Therapeutics utilizes cutting-edge scientific advancements and technologies to develop novel drugs that can improve the lives of patients worldwide.

   Company Address: 44 Milton Avenue Alpharetta 30009 GA
   Company Phone Number: 620-8655   Stock Exchange / Ticker: NASDAQ VIRI
   VIRI is expected to report next financial results on March 13, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Stock Market Announcement

Virios Therapeutics Makes Significant Strides in Advancing Novel Antiviral Therapies for Chronic Diseases in 2024

Published Wed, Feb 28 2024 2:16 PM UTC

In a recent press release, Virios Therapeutics, Inc., a development-stage biotechnology company, shared its remarkable progress and key milestones achieved in 2024. The company, listed on Nasdaq under the symbol VIRI, focuses on pioneering antiviral treatments for debilitating chronic conditions such as fibromyalgia (FM) and long-COVID (LC). This shareholder lette...

Clinical Study

Advancing the Development of IMC-2: A Potential Treatment for Long-COVID Symptoms

Published Mon, Jan 22 2024 2:00 PM UTC

In recent news, Virios Therapeutics has announced its plans to further advance the development of IMC-2 as a potential treatment for symptoms associated with Long-COVID. This article aims to provide an overview of the facts presented in the company's recent statements, focusing on the planned timeline for clinical proof of concept and phase 2 initiatives.Background:Long-COV...

Product Service News

Pioneering Biotechnology: FDA Regulates Virios Therapeutics Inc.'s Long-COVID Treatment Pathway

Published Tue, Jan 2 2024 12:05 PM UTC

Virios Therapeutics, Inc. Advances Long-COVID Treatment with FDA?s NodVirios Therapeutics, Inc., the renowned biotechnology company dedicated to innovating antiviral therapies for chronic diseases, has announced significant progress in the development of its leading candidate treatment for conditions associated with Long-COVID, also termed post-acute sequelae of SARS-CoV-2 i...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com